| HOME >> MEDICINE >> TECHNOLOGY |
PRINCETON, N.J., Feb. 15, 2012 /PRNewswire/ -- IntegriChain Inc., a commercial provider of data and analytic insights to the pharmaceutical industry, announced today the introduction of a new methodology for its DNA: Inventory – Retail solution that adds the ability to report on independent and chain pharmacies' inventory levels, by product NDC code, using actual un-projected data.
(Logo: http://photos.prnewswire.com/prnh/20111130/NY15137LOGO)
Historically, manufacturers have had visibility to wholesaler inventory and a handful of chain warehouses, but no way to directly measure inventory in the overall retail channel.
IntegriChain's new methodology uses a combination of product "sell-in" data, product "returns" data, and actual pharmacy "point-of-sale" data to accurately calculate inventory levels in the downstream retail channel.
"The ability to align actual pharmacy purchases, sales and returns enables us to deliver a complete and timely view of inventory trends for our customers," said Kevin Leininger, IntegriChain CEO. "Finance, forecasters and demand planners need forward channel visibility now more than ever. With blockbuster patent expirations and mounting supply shortages, retail inventory is key to sound business planning."
Through the DNA Inventory: Retail solution, IntegriChain is now able to report an NDC's total units, dollars and days of inventory present in retail distribution centers, stores, and morgues on a weekly basis.
According to Dan Kinney, IntegriChain VP of Information Services, IntegriChain customers are using DNA Inventory to "tighten their pipeline inventory reserves and improve their demand planning efficiency. The bottom line is to fill the highest possible percentage of orders while not tying up undue amounts of capital on the balance sheet."
About Integr
'/>"/>
| SOURCE IntegriChain, Inc. Copyright©2010 PR Newswire. All rights reserved |